Pelabresib is a Small Molecule owned by MorphoSys, and is involved in 5 clinical trials, of which 2 were completed, and 3 are ongoing.
Pelabresib (CPI-0610) is an inhibitor of bromodomain and extra-terminal (BET) proteins (BRD2, BRD3, BRD4, and BRDT). The drug candidate acts on acetyl-lysine binding pockets that target bromodomain-containing proteins to histones and thereby affecting chromatin structure and function. The binding of BET protein bromodomains to chromatin regulates gene expression. The drug candidate arrests the cell cycle progression and leads to apoptosis.
The revenue for Pelabresib is expected to reach a total of $1.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pelabresib NPV Report.
Pelabresib was originated by Constellation Pharmaceuticals and is currently owned by MorphoSys.
Pelabresib (CPI-0610) is under development for the treatment of acute myelocytic leukemia (AML, Acute Myeloblastic Leukemia), myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasms myelofibrosis, primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. The drug candidate is administered orally and is a new molecular entity. It acts by targeting bromodomain and extra-terminal (BET) proteins (BRD2, BRD3, BRD4, and BRDT). It was also under development for the treatment of non-Hodgkin lymphomas including diffuse large cell B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, multiple myeloma.
MorphoSys is commercial-stage biopharmaceutical company that develop monoclonal antibodies for therapeutic and research applications, with focused on the treatment of cancer and autoimmune diseases. The company’s product pipeline includes tafasitamab, pelabresib, cpi-0209, gantenerumab, otilimab, ianalumab, abelacimab, felzartamab, setrusumab, NOV-8, NOV-14 and MOR210. Its Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. The company provides clinical trials for cancer and inflammatory disorders. MorphoSys also conducts research and development activities with pharmaceutical and biotechnology companies. The company owns a regional licensing agreement to develop and commercialize products. It operates in the US. MorphoSys is headquartered in Planegg, Bayern, Germany.
The company reported revenues of (Euro) EUR179.6 million for the fiscal year ended December 2021 (FY2021), a decrease of 45.2% over FY2020. The operating loss of the company was EUR506.2 million in FY2021, compared to an operating profit of EUR26.7 million in FY2020. The net loss of the company was EUR514.5 million in FY2021, compared to a net profit of EUR97.9 million in FY2020. The company reported revenues of EUR95.8 million for the third quarter ended September 2022, an increase of 61.1% over the previous quarter.
Quick View – Pelabresib
|Highest Development Stage|